Trusted Resources: Education
Scientific literature and patient education texts
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis
source: Advances in therapy
year: 2021
authors: Gauthier-Loiselle M,Cloutier M,Toro W,Patel A,Shi S,Davidson M,Bischof M,LaMarca N,Dabbous O
summary/abstract:Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disorder caused by deletion/mutation of the survival motor neuron 1 gene, characterized by progressive loss of motor neurons, resulting in increasing muscular weakness, deteriorating motor function, and, in its most severe form, death before 2 years. Nusinersen, an antisense oligonucleotide that increases expression of the functional SMN protein, was approved for SMA by US and European regulatory agencies in 2016 and 2017, respectively. The indicated regimen requires intrathecal injections every 4 months, following the first four injections during the loading phase. Adherence is integral to treatment success. Adherence to nusinersen may pose particular challenges as most patients with SMA are young children who require complex multidisciplinary care (including ongoing intrathecal treatment administration and potential specialized anesthetic and surgical procedures) at specialized centers. However, real-world data on adherence to nusinersen are limited.
organization: Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, Canada.DOI: 10.1007/s12325-021-01938-w
read more
Related Content
-
Spinal Muscular Atrophy: OverviewWhat is spinal muscular atrophy (SMA)?Sp...
-
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMABiogen announced it intends to initiate ...
-
A Case Series of Paediatric Patients With Spinal Muscular Atrophy Type I Undergoing Scoliosis Correction SurgerySpinal muscular atrophy is a neuromuscul...
-
Improvement in Fine Manual Dexterity in Children With Spinal Muscular Atrophy Type 2 After Nusinersen Injection: A C...Although nusinersen has been demonstrate...
-
Safety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
Spinal Muscular Atrophy (SMA)Spinal muscular atrophy (SMA) is a genet...